Dr Jim Faed
| Position | Senior Lecturer |
|---|---|
| Department | Department of Pathology (Dunedin) |
| Qualifications | BMedSc MB ChB(Otago) FRCPA |
| Research summary | Blood transfusion and Adult Stem Cell Research. Spinal Cord injury repair. |
Research
- Adult mesenchymal stem cells
- clinical trials of spinal cord injury treatment
- learning programme for Medical Laboratory Science
- clinical haemostasis
- blood donor selection and retention
Publications
Brennan, S. O., Mangos, H., & Faed, J. M. (2014). Benign FGB (148Lys→Asn, and 448Arg→Lys), and novel causative y211Tyr→His mutation distinguished by time of flight mass spectrometry in a family with hypofibrinogenaemia. Thrombosis & Haemostasis, 111(4), 679-684. doi: 10.1160/TH13-08-0657
Gulati, A., Faed, J. M., Isbister, G. K., & Duffull, S. B. (2012). Development and evaluation of a prototype of a novel clotting time test to monitor enoxaparin. Pharmaceutical Research, 29(1), 225-235. doi: 10.1007/s11095-011-0537-z
Dear, A., Brennan, S. O., Sheat, M. J., Faed, J. M., & George, P. M. (2007). Acquired dysfibrinogenemia caused by monoclonal production of immunoglobulin λ light chain. Haematologica, 92, e111-e117. doi: 10.3324/haematol.11837
Harkins, C., Hammond-Tooke, G., & Faed, J. (2009). Intravenous immunoglobulin therapy for neurological disorders. New Zealand Medical Journal, 122(1305). Retrieved from http://journal.nzma.org.nz/journal/122-1305/3850/content.pdf
Journal - Research Article
Brennan, S. O., Mangos, H., & Faed, J. M. (2014). Benign FGB (148Lys→Asn, and 448Arg→Lys), and novel causative y211Tyr→His mutation distinguished by time of flight mass spectrometry in a family with hypofibrinogenaemia. Thrombosis & Haemostasis, 111(4), 679-684. doi: 10.1160/TH13-08-0657
Gulati, A., Faed, J. M., Isbister, G. K., & Duffull, S. B. (2012). Development and evaluation of a prototype of a novel clotting time test to monitor enoxaparin. Pharmaceutical Research, 29(1), 225-235. doi: 10.1007/s11095-011-0537-z
Harkins, C., Hammond-Tooke, G., & Faed, J. (2009). Intravenous immunoglobulin therapy for neurological disorders. New Zealand Medical Journal, 122(1305). Retrieved from http://journal.nzma.org.nz/journal/122-1305/3850/content.pdf
Dear, A., Brennan, S. O., Sheat, M. J., Faed, J. M., & George, P. M. (2007). Acquired dysfibrinogenemia caused by monoclonal production of immunoglobulin λ light chain. Haematologica, 92, e111-e117. doi: 10.3324/haematol.11837
